Thesis (Ph. D.)--University of California, Riverside, 2010. / Includes abstract. Available via ProQuest Digital Dissertations. Title from first page of PDF file (viewed May 18, 2010). Includes bibliographical references. Also issued in print.

A esquizofrenia é um transtorno psiquiátrico grave, caracterizado por distúrbios do pensamento, prejuízo da lógica, alterações cognitivas e emocionais, e/ou isolamento social. Apesar da introdução de novos antipsicóticos, um grupo considerável de pacientes ainda é refratário aos tratamentos disponíveis. Além disso, a alta incidência de efeitos adversos leva à baixa adesão ao tratamento em esquizofrênicos. O desenvolvimento de tratamentos mais eficazes e com menor incidência de efeitos adversos, que aumentem a adesão ao tratamento e melhorem a qualidade de vida destes pacientes, é assim altamente desejável. Em uma expedição etnofarmacológica entre os Igbo na Nigéria identificou-se uma preparação a base de plantas usada no tratamento de pacientes com distúrbios mentais. O alcalóide indólico alstonina é o componente majoritário desta preparação, e possui um claro perfil comportamental de antipsicótico atípico em modelos animais de sintomas positivos, com aparentes vantagens em relação à clozapina. Este trabalho teve o objetivo principal de dar continuidade à caracterização de alstonina como fármaco antipsicótico. Demonstramos que este alcalóide aumenta a interação social e previne o déficit de interação social induzido por MK801 em camundongos, sugerindo utilidade da alstonina no manejo de sintomas negativos da esquizofrenia. Quanto ao mecanismo de ação, a avaliação do efeito de alstonina sobre as aminas biogênicas em córtex frontal e estriado de camundongos sugere que este alcalóide potencia a transmissão serotonérgica e aumenta o catabolismo intraneuronal de dopamina. Quanto aos possíveis efeitos adversos, dados preliminares mostram que alstonina não altera os níveis de prolactina, não induz ganho de peso corporal, mas impede a diminuição da glicemia induzida por jejum. Este trabalho confirma o perfil antipsicótico de alstonina bem como a possibilidade de um mecanismo de ação inovador. Os resultados justificam investimento em novos estudos, quer seja para o desenvolvimento de alstonina como fármaco, quer no sentido de trazer inovação farmacodinâmica tão necessária para avançar no tratamento da esquizofrenia. / Schizophrenia is a serious psychiatric illness, characterized by alterations in thought, deficits in logical thinking, changes in cognition and emotion, and/or social isolation. Despite the introduction of newer antipsychotic drugs, a sizable number of patients are still refractory to the available medication. Moreover, the high incidence of side effects determines the low adhesion of patients to treatments. The development of more efficacious treatments with lower incidence of side effects, ameliorating adhesion to treatment and improving patient’s quality of life is, therefore, sorely wanted. During an ethnopharmacological expedition among the Igbo in Nigeria, a plant based treatment to mentally ill patients was identified. The indole alkaloid alstonine is the major component of this remedy and shown to have a clear behavioral profile of an atypical antipsychotic in rodent models, apparently with advantages in comparison to clozapine. This study had the main purpose of continuing the characterization of alstonine as an antipsychotic drug. We show that this alkaloid increases social interaction and prevents MK801-induced social withdrawal in mice, pointing to its utility in managing negative symptoms of schizophrenia. Regarding its mechanism of action, the effects of alstonine on biogenic amines in mice frontal cortex and striatum suggest that it enhances serotonergic neurotransmission and increases the intra neuronal catabolism of dopamine. In relation to possible side effects, preliminary data suggest that alstonine does not affect prolactin levels, does not induce gains in body weight, but prevents the expected fasting-induced decrease in glucose levels. This study corroborates the antipsychotic profile of alstonine, as well as the possibility of an innovative mechanism of action. These results justify further studies either to develop alstonine as a medication, or to bring pharmacodynamic innovation so sorely needed to move forward in the treatment of schizophrenia.

The aim of this thesis was to determine the content of biogenic amines and polyamines, specifically putrescine (PUT), spermidine (SPD) and spermine (SPM) in mutton meat during storage and heat treatment. The meat of slaughter animals is rich in these amines but, unfortunately, data on the content of mutton meat whether in slaughter bodies as well as during storage or heat treatments in the literature are still missing. The samples were provided by small farmers and the animals were hybrids of several breeds. The samples were taken from the thigh and back. The samples of lamb meat were frozen and the ones were watched from 0-6 months. The samples of leg were cooled and packed into three different types of packaging. It was the type of packaging in a polyethylene bag (PE), vacuum packed (VP) and controlled atmosphere packaging (MAP). All the samples were analyzed in the days and also on the initial concentration at day 0. For frozen and cooled (chilled) samples which were stored in PE and VP was observed the decrease in all monitored amines. Only the packaging in MAP occurred in the SPD to a slight increase over the initial content. From heat treatments were performed usual preparations of the meals which are made in central Europe and the meals were cooked on particular days. The highest decrease was measured in roasted meat, then stewed and cooked meat in this order. Reported data are comparable to published data for pork and beef meat stored under the same or similar conditions. I think that these data can help to extend the data in the literature.

A esquizofrenia é um transtorno psiquiátrico grave, caracterizado por distúrbios do pensamento, prejuízo da lógica, alterações cognitivas e emocionais, e/ou isolamento social. Apesar da introdução de novos antipsicóticos, um grupo considerável de pacientes ainda é refratário aos tratamentos disponíveis. Além disso, a alta incidência de efeitos adversos leva à baixa adesão ao tratamento em esquizofrênicos. O desenvolvimento de tratamentos mais eficazes e com menor incidência de efeitos adversos, que aumentem a adesão ao tratamento e melhorem a qualidade de vida destes pacientes, é assim altamente desejável. Em uma expedição etnofarmacológica entre os Igbo na Nigéria identificou-se uma preparação a base de plantas usada no tratamento de pacientes com distúrbios mentais. O alcalóide indólico alstonina é o componente majoritário desta preparação, e possui um claro perfil comportamental de antipsicótico atípico em modelos animais de sintomas positivos, com aparentes vantagens em relação à clozapina. Este trabalho teve o objetivo principal de dar continuidade à caracterização de alstonina como fármaco antipsicótico. Demonstramos que este alcalóide aumenta a interação social e previne o déficit de interação social induzido por MK801 em camundongos, sugerindo utilidade da alstonina no manejo de sintomas negativos da esquizofrenia. Quanto ao mecanismo de ação, a avaliação do efeito de alstonina sobre as aminas biogênicas em córtex frontal e estriado de camundongos sugere que este alcalóide potencia a transmissão serotonérgica e aumenta o catabolismo intraneuronal de dopamina. Quanto aos possíveis efeitos adversos, dados preliminares mostram que alstonina não altera os níveis de prolactina, não induz ganho de peso corporal, mas impede a diminuição da glicemia induzida por jejum. Este trabalho confirma o perfil antipsicótico de alstonina bem como a possibilidade de um mecanismo de ação inovador. Os resultados justificam investimento em novos estudos, quer seja para o desenvolvimento de alstonina como fármaco, quer no sentido de trazer inovação farmacodinâmica tão necessária para avançar no tratamento da esquizofrenia. / Schizophrenia is a serious psychiatric illness, characterized by alterations in thought, deficits in logical thinking, changes in cognition and emotion, and/or social isolation. Despite the introduction of newer antipsychotic drugs, a sizable number of patients are still refractory to the available medication. Moreover, the high incidence of side effects determines the low adhesion of patients to treatments. The development of more efficacious treatments with lower incidence of side effects, ameliorating adhesion to treatment and improving patient’s quality of life is, therefore, sorely wanted. During an ethnopharmacological expedition among the Igbo in Nigeria, a plant based treatment to mentally ill patients was identified. The indole alkaloid alstonine is the major component of this remedy and shown to have a clear behavioral profile of an atypical antipsychotic in rodent models, apparently with advantages in comparison to clozapine. This study had the main purpose of continuing the characterization of alstonine as an antipsychotic drug. We show that this alkaloid increases social interaction and prevents MK801-induced social withdrawal in mice, pointing to its utility in managing negative symptoms of schizophrenia. Regarding its mechanism of action, the effects of alstonine on biogenic amines in mice frontal cortex and striatum suggest that it enhances serotonergic neurotransmission and increases the intra neuronal catabolism of dopamine. In relation to possible side effects, preliminary data suggest that alstonine does not affect prolactin levels, does not induce gains in body weight, but prevents the expected fasting-induced decrease in glucose levels. This study corroborates the antipsychotic profile of alstonine, as well as the possibility of an innovative mechanism of action. These results justify further studies either to develop alstonine as a medication, or to bring pharmacodynamic innovation so sorely needed to move forward in the treatment of schizophrenia.

abstract: Spatiotemporal processing in the mammalian olfactory bulb (OB), and its analog, the invertebrate antennal lobe (AL), is subject to plasticity driven by biogenic amines. I study plasticity using honey bees, which have been extensively studied with respect to nonassociative and associative based olfactory learning and memory. Octopamine (OA) release in the AL is the functional analog to epinephrine in the OB. Blockade of OA receptors in the AL blocks plasticity induced changes in behavior. I have now begun to test specific hypotheses related to how this biogenic amine might be involved in plasticity in neural circuits within the AL. OA acts via different receptor subtypes, AmOA1, which gates calcium release from intracellular stores, and AmOA-beta, which results in an increase of cAMP. Calcium also enters AL interneurons via nicotinic acetylcholine receptors, which are driven by acetylcholine release from sensory neuron terminals, as well as through voltage-gated calcium channels. I employ 2-photon excitation (2PE) microscopy using fluorescent calcium indicators to investigate potential sources of plasticity as revealed by calcium fluctuations in AL projection neuron (PN) dendrites in vivo. PNs are analogous to mitral cells in the OB and have dendritic processes that show calcium increases in response to odor stimulation. These calcium signals frequently change after association of odor with appetitive reinforcement. However, it is unclear whether the reported plasticity in calcium signals are due to changes intrinsic to the PNs or to changes in other neural components of the network. My studies were aimed toward understanding the role of OA for establishing associative plasticity in the AL network. Accordingly, I developed a treatment that isolates intact, functioning PNs in vivo. A second study revealed that cAMP is a likely component of plasticity in the AL, thus implicating the AmOA-beta; receptors. Finally, I developed a method for loading calcium indicators into neural components of the AL that have yet to be studied in detail. These manipulations are now revealing the molecular mechanisms contributing to associative plasticity in the AL. These studies will allow for a greater understanding of plasticity in several neural components of the honey bee AL and mammalian OB. / Dissertation/Thesis / Doctoral Dissertation Neuroscience 2014

A esquizofrenia é um transtorno psiquiátrico grave, caracterizado por distúrbios do pensamento, prejuízo da lógica, alterações cognitivas e emocionais, e/ou isolamento social. Apesar da introdução de novos antipsicóticos, um grupo considerável de pacientes ainda é refratário aos tratamentos disponíveis. Além disso, a alta incidência de efeitos adversos leva à baixa adesão ao tratamento em esquizofrênicos. O desenvolvimento de tratamentos mais eficazes e com menor incidência de efeitos adversos, que aumentem a adesão ao tratamento e melhorem a qualidade de vida destes pacientes, é assim altamente desejável. Em uma expedição etnofarmacológica entre os Igbo na Nigéria identificou-se uma preparação a base de plantas usada no tratamento de pacientes com distúrbios mentais. O alcalóide indólico alstonina é o componente majoritário desta preparação, e possui um claro perfil comportamental de antipsicótico atípico em modelos animais de sintomas positivos, com aparentes vantagens em relação à clozapina. Este trabalho teve o objetivo principal de dar continuidade à caracterização de alstonina como fármaco antipsicótico. Demonstramos que este alcalóide aumenta a interação social e previne o déficit de interação social induzido por MK801 em camundongos, sugerindo utilidade da alstonina no manejo de sintomas negativos da esquizofrenia. Quanto ao mecanismo de ação, a avaliação do efeito de alstonina sobre as aminas biogênicas em córtex frontal e estriado de camundongos sugere que este alcalóide potencia a transmissão serotonérgica e aumenta o catabolismo intraneuronal de dopamina. Quanto aos possíveis efeitos adversos, dados preliminares mostram que alstonina não altera os níveis de prolactina, não induz ganho de peso corporal, mas impede a diminuição da glicemia induzida por jejum. Este trabalho confirma o perfil antipsicótico de alstonina bem como a possibilidade de um mecanismo de ação inovador. Os resultados justificam investimento em novos estudos, quer seja para o desenvolvimento de alstonina como fármaco, quer no sentido de trazer inovação farmacodinâmica tão necessária para avançar no tratamento da esquizofrenia. / Schizophrenia is a serious psychiatric illness, characterized by alterations in thought, deficits in logical thinking, changes in cognition and emotion, and/or social isolation. Despite the introduction of newer antipsychotic drugs, a sizable number of patients are still refractory to the available medication. Moreover, the high incidence of side effects determines the low adhesion of patients to treatments. The development of more efficacious treatments with lower incidence of side effects, ameliorating adhesion to treatment and improving patient’s quality of life is, therefore, sorely wanted. During an ethnopharmacological expedition among the Igbo in Nigeria, a plant based treatment to mentally ill patients was identified. The indole alkaloid alstonine is the major component of this remedy and shown to have a clear behavioral profile of an atypical antipsychotic in rodent models, apparently with advantages in comparison to clozapine. This study had the main purpose of continuing the characterization of alstonine as an antipsychotic drug. We show that this alkaloid increases social interaction and prevents MK801-induced social withdrawal in mice, pointing to its utility in managing negative symptoms of schizophrenia. Regarding its mechanism of action, the effects of alstonine on biogenic amines in mice frontal cortex and striatum suggest that it enhances serotonergic neurotransmission and increases the intra neuronal catabolism of dopamine. In relation to possible side effects, preliminary data suggest that alstonine does not affect prolactin levels, does not induce gains in body weight, but prevents the expected fasting-induced decrease in glucose levels. This study corroborates the antipsychotic profile of alstonine, as well as the possibility of an innovative mechanism of action. These results justify further studies either to develop alstonine as a medication, or to bring pharmacodynamic innovation so sorely needed to move forward in the treatment of schizophrenia.

No description available.

Orientador: Giuseppina Pace Pereira Lima / Resumo: O cozimento além de facilitar a digestibilidade e a palatabilidade dos vegetais, pode alterar a biodisponibilidade de micronutrientes. As couves-flores são normalmente consumidas após processamento térmico e apresentam níveis elevados de compostos bioativos que influenciam na saúde humana, especialmente na prevenção as doenças crônicas. Estes compostos possuem atividade antioxidante que confere proteção e auxilia o organismo humano a eliminar os radiacias livres, componentes centrais das regulações metabólicas induzidas por doenças crônicas. Desta forma, o objetivo deste estudo foi avaliar o efeito do tempo e tipo de cozimento (fervura, vapor e micro-ondas) sobre as características bioquímicas de quatro genótipos de couve-flor colorida (‘Verde di Macerata’, ‘Cheddar’, ‘Forata’ e ‘Graffiti’). Em um primeiro momento, foi determinado o perfil físico-químico das couves-flores coloridas. Os floretes foram submetidos aos tratamentos térmicos por 5 e 10 min e após foram realizadas as análises físico-químicas. O processamento em ebulição resultou em perdas significativas de sólidos solúveis totais e carboidratos solúveis totais, diferentemente dos métodos onde foram utilizadas menores quantidades de água para o processamento das inflorescências (i.e., micro-ondas e vapor). Os métodos a vapor e micro-ondas resultaram em valores superiores de sólidos solúveis, independente do genótipo analisado. O cozimento dos floretes em ebulição reduziu significativamente os teores da maioria dos co... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: The cooking process, besides facilitating the digestibility and palatability of vegetables, can alter the bioavailability of micronutrients. The cauliflowers are usually consumed after a thermal process and present high levels of bioactive compounds that positively affect the human health, particularly in chronic disease prevention. The compounds possess antioxidant activity that provides protection and assists the human organism in eliminating free radicals, central compounds in metabolic regulations induced by chronic diseases. Thus, the objective of this study was to evaluate the effect of time and cooking procedure (boiling, steaming and microwaving) over the biochemical characteristics of four genotypes of colored cauliflowers (‘Verde di Macerata’, ‘Cheddar’, ‘Forata’ e ‘Gradffiti’). Firstly, the physicochemical profile of the colored cauliflowers was determined. The cauliflowers were subjected to the thermal processes for 5 and 10 minutes and physicochemical analysis were performed. The boiling process resulted in significant losses of total soluble solids and total soluble carbohydrates, unlike the methods where smaller amounts of water were used for processing the inflorescences (i.e., microwaving and steaming). The steaming and microwaving methods resulted in superior values of soluble solids, independently of the analyzed genotype. The cooking of the inflorescences by boiling reduced significantly the contents of the majority of the analyzed chemical compounds (titr... (Complete abstract click electronic access below) / Doutor

Rats lesioned shortly after birth with 6-hydroxydopamine (6-OHDA; 134 μg icv) represent a near-ideal model of severe Parkinson's disease because of the near-total destruction of nigrostriatal dopaminergic fibers. The element manganese, an essential cofactor for many enzymatic reactions, itself in toxic amount, replicates some clinical features similar to those of Parkinson's disease. The aim of this study was to examine the effect of neonatal manganese exposure on 6-OHDA modeling of Parkinson's disease in rats. Manganese (MnCl 2·4H 2O) 10,000 ppm was included in the drinking water of pregnant Wistar rats from the time of conception until the 21st day after delivery, the age when neonatal rats were weaned. Control rats consumed tap water. Other groups of neonatal rat pups, on the 3rd day after birth, were pretreated with desipramine (20 mg/kg ip 1 h) prior to bilateral icv administration of 6-OHDA (30, 60, or 137 μg) or its vehicle saline-ascorbic (0.1%) (control). At 2 months after birth, in rats lesioned with 30, 60, or 134 μg 6-OHDA, endogenous striatal dopamine (DA) content was reduced, respectively, by 66, 92, and 98% (HPLC/ED), while co-exposure of these groups to perinatal manganese did not magnify the DA depletion. However, there was prominent enhancement of DA D 1 agonist (i.e., SKF 38393)-induced oral activity in the group of rats exposed perinatally to manganese and also treated neonatally with the 30 mg/kg dose of 6-OHDA. The 30 mg/kg 6-OHDA group, demonstrating cataleptogenic responses to SCH 23390 (0.5 mg/kg) and haloperidol (0.5 mg/kg ip), developed resistance if co-exposed to perinatal manganese. In the group exposed to manganese and lesioned with the 60 mg/kg dose of 6-OHDA, there was a reduction in D2 agonist (i.e., quinpirole, 0.1 mg/kg)-induced yawning. The series of findings demonstrate that ontogenetic exposure to manganese results in an enhancement of behavioral toxicity to a moderate dose of 6-OHDA, despite the fact that there is no enhanced depletion of striatal DA depletion by the manganese treatment.

To assess the possible modulatory effects of noradrenergic and serotoninergic neurons on dopaminergic neuronal activity, the noradrenergic and serotoninergic neurotoxins DSP-4 N-(2-chlorethyl)-N-ethyl-2-bromobenzylamine (50.0 mg/kg, sc) and 5,7- dihydroxytryptamine (5,7-DHT) (37.5 μg icv, half in each lateral ventricle), respectively, were administered to Wistar rats on the first and third days of postnatal ontogeny, and dopamine (DA) agonist-induced behaviors were assessed in adulthood. At eight weeks, using an HPLC/ED technique, DSP-4 treatment was associated with a reduction in NE content of the corpus striatum (> 60%), hippocampus (95%), and frontal cortex (> 85%), while 5,7-DHT was associated with an 80-90% serotonin reduction in the same brain regions. DA content was unaltered in the striatum and the cortex. In the group lesioned with both DSP-4 and 5,7-DHT, quinpirole-induced (DA D2-agonist-agonist) yawning, 7-hydroxy-DPAT-induced (DA D3 agonist) yawning, and apomorphine-induced (non-selective DA agonist) stereotypies were enhanced. However, SKF 38393-induced (DA D1 agonist) oral activity was reduced in the DSP-4 + 5,7-DHT group. These findings demonstrate that DA D2- and D3-agonist-induced behaviors are enhanced while DA D1-agonist-induced behaviors are suppressed in adult rats in which brain noradrenergic and serotoninergic innervation of the brain has largely been destroyed. This study indicates that noradrenergic and serotoninergic neurons have a great impact on the development of DA receptor reactivity (sensitivity).